Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425344 | 0.83 | PIK3CD (0.42) | PIK3CDMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL24783413 | 0.82 | PIK3CD (0.32) | PIK3CDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15298471 | 0.82 | MEN1 (0.38) | PIK3CDMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL15298470 | 0.82 | MEN1 (0.38) | PIK3CDMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL3421109 | 0.82 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL16849182 | 0.79 | PIK3CD (0.47) | PIK3CD | |
| SCHEMBL24491637 | 0.79 | GBA1 (0.33) | — | |
| SCHEMBL425355 | 0.77 | TSHR (0.43) | PIK3CDMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL18926695 | 0.76 | PIK3CD (0.58) | PIK3CDSMN1; SMN2 | |
| SCHEMBL24842013 | 0.74 | PIK3CD (0.47) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | PIK3CD 2669/4885MEN1 1213/4885KMT2A 64/4885 |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL12, RPL13A | PIK3CD 1374/4885MEN1 1867/4885KMT2A 3895/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | PIK3CD 2669/4885MEN1 1213/4885KMT2A 64/4885 |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | PIK3CD 2864/4885MEN1 540/4885KMT2A 4414/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | PIK3CD 2864/4885MEN1 540/4885KMT2A 4414/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | PIK3CD 2864/4885MEN1 540/4885KMT2A 4414/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | PIK3CD 2759/4885MEN1 896/4885KMT2A 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.